ClinicalTrials.gg
RecruitingNCT06844058IEH-RTCUpdated Mar 26, 2025

Islamic-Oriented vs. Standard Ericksonian Hypnotherapy for Anxiety and Depression

An interventional study of Islamic-Oriented Ericksonian Hypnotherapy (IEH) and Standard Ericksonian Hypnotherapy (SEH) in Anxiety Disorders and Depressive Disorder, sponsored by Istanbul Nisantasi University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Istanbul Nisantasi University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,266 studies in Anxiety Disorders with a site in Turkey — 236 open to participants now, 277 under way, none of them phase 3. Anxiety Disorders · Turkey.

Planned enrollment
383rd of 1,124
90 · median 78
Started
2025
with 243 others
No phase
1,118 of 1,266
212 open now
Primary completion
2025-06
later than 76 of 276 live
Registered
757th of 1,266
by date

Among the 1,266 studies in Anxiety Disorders with a site in Turkey, this one is the 383rd largest by planned enrollment of the 1,124 interventional ones that give a count, is one of 244 that started in 2025, is one of 1,118 with no phase, reaches primary completion later than 76 of the 276 other live ones, and was the 757th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

236 of the 1,266 studies in Anxiety Disorders with a site in Turkey are open now. Recruiting first, the newest first:

231 more — sign in →

All 236 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,266 studies in Anxiety Disorders with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial (RCT) aims to compare the effectiveness of Islamic-Oriented Ericksonian Hypnotherapy (IEH) and Standard Ericksonian Hypnotherapy (SEH) in reducing symptoms of anxiety and depression. The study will enroll 90 participants with mild to moderate anxiety and depression, who will be randomly assigned to one of three groups: (1) IEH intervention, (2) SEH intervention, or (3) control group (no intervention). Participants in the intervention groups will receive 12 weekly hypnotherapy sessions, each lasting 60 minutes. The primary outcomes include changes in Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) scores from baseline to post-intervention and at a 4-week follow-up.

The study will also assess whether religious belief levels moderate the effects of the intervention using the OK-Religious Attitude Scale. Data collection will be performed at Istanbul Nişantaşı University, and ethical approval has been obtained.

Read the detailed description

This randomized controlled trial evaluates the differential effects of Islamic-Oriented Ericksonian Hypnotherapy (IEH) and Standard Ericksonian Hypnotherapy (SEH) in alleviating symptoms of anxiety and depression among religious Muslim adults. The primary objective is to examine whether the integration of Islamic religious elements into Ericksonian hypnotherapy enhances clinical outcomes compared to its standard application.

The study follows a parallel-group design with three arms: IEH, SEH, and a no-intervention control. Ninety participants (30 per group) are randomized using stratified block randomization based on age and gender. All intervention sessions are manualized, delivered by trained clinical psychologists, and conducted weekly over 12 weeks (each lasting 60 minutes).

IEH sessions incorporate culturally and religiously adapted therapeutic elements, such as Quranic metaphors, Islamic imagery, and spiritual affirmations, in line with the Ericksonian framework. SEH sessions utilize traditional hypnotic techniques including metaphorical storytelling, guided imagery, and indirect suggestions, without religious content.

Primary outcome measures include changes in Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) scores from baseline to Week 12 (post-intervention) and Week 16 (follow-up). Secondary analyses will investigate whether religiosity levels (measured via the OK-Religious Attitude Scale) moderate treatment effects. Blinded outcome assessors will ensure unbiased data collection.

This study addresses the need for culturally responsive mental health interventions within Muslim populations. Ethical approval was obtained from the İstanbul Nişantaşı University Ethics Committee (Approval No: 20250103-27). Results are expected to contribute to evidence-based development of spiritually integrated psychotherapeutic models for anxiety and depression.

03

Conditions studied

  • Anxiety Disorders
  • Depressive Disorder

Keywords

  • Hypnotherapy
  • Ericksonian Hypnosis
  • Islamic Psychology
  • Anxiety Reduction
  • Depression Treatment
  • Culturally Adapted Psychotherapy
  • Religious-Based Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Muslim individuals aged 18-65 years.
  • Mild to moderate anxiety and/or depression symptoms (assessed via Beck
  • Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI)).
  • No formal psychiatric diagnosis but experiencing psychological distress.
  • High religious belief levels, assessed via OK-Religious Attitude Scale.
  • Not currently receiving psychotherapy or psychotropic medication.
  • Ability to give and complete the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric disorders (schizophrenia, bipolar disorder, severe MDD).
  • Current use of psychotropic medication or undergoing psychotherapy.
  • History of substance abuse or dependence.
  • Diagnosed dissociative disorders ( for hypnosis).
  • Cognitive impairment affecting comprehension of intervention.
  • Severe medical conditions that may interfere with participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Islamic-Oriented Ericksonian Hypnotherapy (IEH) Group

    Participants receive 12 weekly sessions of Islamic-Oriented Ericksonian Hypnotherapy (IEH), which integrates faith-based imagery, Quranic metaphors, and religiously adapted hypnotic suggestions alongside standard Ericksonian techniques. Each session lasts 60 minutes.

    Behavioral: Islamic-Oriented Ericksonian Hypnotherapy (IEH)

  • Active comparator
    Standard Ericksonian Hypnotherapy (SEH) Group

    Participants receive 12 weekly sessions of Standard Ericksonian Hypnotherapy (SEH), using metaphorical storytelling, indirect suggestions, guided imagery, and hypnotic language patterns without religious integration. Each session lasts 60 minutes.

    Behavioral: Standard Ericksonian Hypnotherapy (SEH)

  • No intervention
    Control Group (No Intervention)

    Participants do not receive any intervention but will complete assessments at baseline, post-intervention (Week 12), and follow-up (Week 16).

Interventions

  • BehavioralIslamic-Oriented Ericksonian Hypnotherapy (IEH)

    This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate: Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression.

  • BehavioralStandard Ericksonian Hypnotherapy (SEH)

    Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes: Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements.

06

What researchers measure

Primary outcomes

  1. Beck Depression Inventory-II (BDI-II)

    The study evaluates the effectiveness of Islamic-Oriented Ericksonian Hypnotherapy (IEH) vs. Standard Ericksonian Hypnotherapy (SEH) vs. No Intervention in reducing depressive symptoms. Depression severity will be assessed using the Beck Depression Inventory-II (BDI-II), comparing baseline, post-intervention (Week 12), and follow-up (Week 16) scores.

    Time frame: Baseline, Week 12 (post-intervention), Week 16 (follow-up)

  2. Beck Anxiety Inventory (BAI)

    The study measures reductions in anxiety symptoms among participants receiving IEH, SEH, or no intervention. Anxiety severity will be assessed using the Beck Anxiety Inventory (BAI), comparing scores from baseline to post-intervention and follow-up.

    Time frame: Baseline, Week 12, Week 16

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD) will be shared upon publication of the study results in a peer-reviewed journal. The shared dataset will include anonymized scores from outcome measures (e.g., BDI-II, BAI) and will exclude any personally identifiable information. Data will be available upon reasonable request for research purposes.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: IPD and supporting information will be available after publication of study results and will remain accessible for five years post-publication.

Access criteria: Researchers requesting access must submit a formal request specifying their intended use of the data. Access will be granted upon institutional review and approval by the research team. Requests can be made by contacting the corresponding author via email.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 5 months is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Jan 15, 2025
Primary completionEst.
Jun 25, 2025
CompletionEst.
Aug 15, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844058
Lead sponsor
Istanbul Nisantasi University
Responsible party
Metin Çınaroğlu (Principal Investigator, Istanbul Nisantasi University) — Principal investigator
First posted
Feb 25, 2025
Start date
Jan 15, 2025
Primary completion
Jun 25, 2025 (estimated)
Completion
Aug 15, 2025 (estimated)
Last update
Mar 26, 2025

Study contacts

Metin Çınaroğlu, Phd
Contact
metin.cinaroglu@nisantasi.edu.tr
+905324732070
Gözde Mert, Phd
Contact
gozde.mert@nisantasi.edu.tr
+905359403399
Metin Çınaroğlu, Phd
principal investigator · Istanbul Nisantasi Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion